A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

BACKGROUND: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Tingyan, Yin, Sheng, Zhu, Jianqing, Zhang, Ping, Liu, Jihong, Xiang, Libing, Zhu, Yaping, Wu, Sufang, Chen, Xiaojun, Wang, Xipeng, Teng, Yincheng, Zhu, Tao, Yu, Aijun, Zhang, Yingli, Feng, Yanling, Huang, He, Bao, Wei, Li, Yanli, Jiang, Wei, Li, Jiarui, Ai, Zhihong, Zhang, Wei, Jia, Huixun, Zhang, Yuqin, Jiang, Rong, Zhang, Jiejie, Gao, Wen, Luan, Yuting, Zang, Rongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2020
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189080/
https://www.ncbi.nlm.nih.gov/pubmed/32319233
http://dx.doi.org/10.3802/jgo.2020.31.e61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189080/
https://www.ncbi.nlm.nih.gov/pubmed/32319233
http://dx.doi.org/10.3802/jgo.2020.31.e61

Ejemplares similares